International Journal of Endocrinology, Volume 2024, Issue 1, 2024.The majority of acromegaly and gigantism are caused by growth hormone‐secreting pituitary neuroendocrine tumors (PitNETs). Most cases can be cured or controlled by surgery, medical therapy, and/or radiotherapy. However, a few of these tumors are resistant to traditional therapy and always have a poor prognosis.
Xiaojuan Zhang +4 more
wiley +1 more source
Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. [PDF]
, 2016 This work is licensed under a Creative Commons Attribution 3.0 Unported LicenseBACKGROUND: Long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in acromegaly.
Adelman +20 more
core +2 more sources
Serum N-Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism [PDF]
, 2016 BACKGROUND: N‐terminal type III procollagen propeptide (PIIINP) is a biomarker of soft tissue proliferation. Hypersomatotropism (HS) is associated with soft tissue proliferation.
Church, D B +4 more
core +2 more sources
AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. [PDF]
, 2019 Background: Pituitary adenomas have a high disease burden due to tumor growth/ invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be ...
Cano González, David A. +2 more
core
ALL-CAUSE MORTALITY IN PATIENTS WITH ACROMEGALY TREATED WITH PEGVISOMANT AN ACROSTUDY ANALYSIS.
European Journal of Endocrinology, 2020 OBJECTIVE To examine all-cause mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including insulin-like growth factor I (IGF-I).
N. Tritos +8 more
semanticscholar +1 more source
Tratamiento médico de tumores hipofisarios
Revista Médica Clínica Las Condes, 2013 Se presentan los diferentes tipos de tumores hipofisiarios y para cada uno las opciones de tratamiento médico disponibles actualmente. Se detallan sus indicaciones, los resultados que se estima posibles, sus efectos secundarios y contraindicaciones.
Dr. C. Pedro Becker
doaj +1 more source
Expression of a glycosylphosphatidylinositol-anchored ligand, growth hormone, blocks receptor signalling [PDF]
, 2012 We have investigated the interaction between GH (growth hormone) and GHR (GH receptor). We previously demonstrated that a truncated GHR that possesses a transmembrane domain but no cytoplasmic domain blocks receptor signalling.
Aiden H. Riley +29 more
core +3 more sources
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study [PDF]
, 2020 Emmanuelle Kuhn +12 more
openalex +1 more source
European Journal of Endocrinology, 2020 Current guidelines recommend the use of somatostatin receptor ligands (LA-SRLs) first when surgery fails to correct GH/IGF-I hypersecretion. In this article, a pro- and contra debate outlines which arguments are in favour and which are against ...
A. J. Lely +5 more
semanticscholar +1 more source